Microglia Modulation Therapies

Introduction

Microglia Modulation Therapies represent a cutting-edge approach in neurodegenerative disease treatment, targeting the resident immune cells of the central nervous system. This page provides comprehensive information about therapeutic strategies aimed at modulating microglial function to promote neuroprotection and reduce neuroinflammation in Alzheimer’s disease, Parkinson’s disease, ALS, and other neurodegenerative disorders.

^{1Microglia in Alzheimer's disease. J Exp Med. 20222022 · DOI 10.1084/jem.20212404Open reference}

Pathway Diagram

flowchart TD
    microglia["microglia"]
    TREM2_APOE_pathway["TREM2-APOE pathway"]
    TREM2_APOE_pathway -->|"regulates"| microglia
    TNF["TNF"]
    TNF -->|"secreted_by"| microglia
    TNF__["TNF-alpha"]
    TNF__ -->|"secreted_by"| microglia
    ULK1["ULK1"]
    ULK1 -->|"expressed in"| microglia
    neuroinflammation["neuroinflammation"]
    neuroinflammation -->|"affects"| microglia
    Alzheimer_s_disease["Alzheimer's disease"]
    Alzheimer_s_disease -->|"affects"| microglia
    aging["aging"]
    aging -->|"affects"| microglia
    style microglia fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style TREM2_APOE_pathway fill:#4a148c,stroke:#ce93d8,color:#ce93d8
    style TNF fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style TNF__ fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style ULK1 fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style neuroinflammation fill:#4a0000,stroke:#ef5350,color:#ef5350
    style Alzheimer_s_disease fill:#4a0000,stroke:#ef5350,color:#ef5350
    style aging fill:#4a0000,stroke:#ef5350,color:#ef5350

Knowledge graph relationships for microglia (1675 total edges in KG)

Overview

Microglia are the primary immune cells of the brain and spinal cord, constituting approximately 10-15% of all cells in the central nervous system. These cells originate from yolk sac progenitors during embryonic development and self-renew throughout life under healthy conditions. In neurodegenerative diseases, microglia undergo dramatic phenotypic changes that can be either beneficial or detrimental to neuronal health. ^{2Gray SG. TREM2 and neuroinflammation. Front Neurol. 20232023 · DOI 10.3389/fneur.2023.892345Open reference}

Dysregulated microglial activity contributes to neurodegeneration through multiple mechanisms, including chronic neuroinflammation, excessive synaptic pruning, and failed clearance of pathological protein aggregates. Modulating microglial function has emerged as a promising therapeutic strategy that may address upstream mechanisms of neuronal loss, potentially providing disease-modifying effects rather than merely symptomatic relief. ^{3CSF-1R inhibition for neurodegenerative diseases. Nat Rev Neurol. 20222022 · DOI 10.1038/s41582-022-00672-1Open reference}

Microglia in Neurodegeneration

Beneficial Functions

Under normal conditions, microglia perform essential roles in brain homeostasis:

• Surveillance: Continuous monitoring of the brain environment through highly motile processes that extend and retract every few minutes, allowing rapid detection of any disturbances

• Phagocytosis: Clearance of debris, dead neurons, and pathological protein aggregates including amyloid-beta plaques and alpha-synuclein inclusions

• Support: Release of neurotrophic factors including BDNF (Brain-Derived Neurotrophic Factor) that support neuronal survival and synaptic plasticity

• Repair: Promotion of tissue remodeling and wound healing following injury

• Synaptic Pruning: During development, microglia eliminate excess synapses to refine neural circuits; this process becomes dysregulated in disease states

Detrimental Functions

In neurodegenerative diseases, microglia can adopt a hyperactivated state that promotes pathology:

• Chronic Inflammation: Sustained release of pro-inflammatory cytokines including IL-1β, TNF-α, and IL-6 creates a neurotoxic environment

• Excessive Synaptic Pruning: Over-elimination of synapses correlates with cognitive decline in both Alzheimer’s and Parkinson’s disease

• NLRP3 Inflammasome: Activation leads to caspase-1 activation and subsequent IL-1β and IL-18 production

• TREM2 Dysfunction: Loss-of-function variants in TREM2 impair microglial phagocytosis of amyloid deposits and increase Alzheimer’s disease risk

• Reactive Microgliosis: Proliferation and clustering around sites of pathology, sometimes forming donut-shaped structures around amyloid plaques

Therapeutic Approaches

TREM2 Targeting

Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) is a surface receptor on microglia that recognizes lipid aggregates and apolipoproteins. Genetic variants in TREM2 significantly modify Alzheimer’s disease risk.

TREM2 Agonists:

• AL002: Anti-TREM2 antibody designed to activate TREM2 signaling pathways, enhancing microglial phagocytic capacity

• AL003: TREM2-modulating antibody with different mechanism of action

• PY314: TREM2-targeting antibody in preclinical development

Mechanism: These antibodies enhance microglial phagocytosis of amyloid-beta aggregates, promote the formation of disease-associated microglia (DAM) phenotype, and may reduce plaque burden

Clinical Status: Multiple Phase I and Phase II trials ongoing for Alzheimer’s disease

References: ^[1]^,^^[2]^

CSF-1R Inhibition

Colony-Stimulating Factor 1 Receptor (CSF-1R) is critical for microglial survival, proliferation, and pro-inflammatory activation. Inhibition can reduce microglial numbers and inflammatory phenotype.

Purpose: Reduce microglial proliferation, decrease pro-inflammatory activation, and shift microglia toward a more protective phenotype

Drugs:

• PLX3397 (Pexidartinib): CSF-1R antagonist approved for tenosynovial giant cell tumor; being repurposed for neurodegenerative diseases

• PLX5622: CSF-1R inhibitor with excellent CNS penetration in preclinical studies

• BLZ945: Highly selective CSF-1R inhibitor showing promise in ALS models

Clinical Status:

• Preclinical studies demonstrate reduced neuroinflammation and improved outcomes in AD and PD models

• Several Phase I trials completed, Phase II trials ongoing for Alzheimer’s disease and ALS

• Challenge: Balancing microglial depletion with loss of protective functions

References: ^[3]^

NLRP3 Inflammasome Inhibitors

The NLRP3 inflammasome is a key driver of microglial inflammation, converting pro-IL-1β to active IL-1β through caspase-1 activation.

Purpose: Block IL-1β production and release from activated microglia, reducing chronic neuroinflammation

Drugs:

• MCC950: Potent and selective NLRP3 inhibitor; showed promise in preclinical models but development paused due to liver toxicity

• Dapansutrile (OLT1177): Oral NLRP3 inhibitor with improved safety profile; in clinical trials for inflammatory conditions

• Tranilast: Approved anti-allergic drug with NLRP3 inhibitory activity being repurposed

Clinical Status: Several candidates in Phase I/II trials for inflammatory conditions; neuro-specific trials planned

References: ^[4]^

BTK Inhibition

Bruton’s Tyrosine Kinase (BTK) is expressed in microglia and regulates multiple inflammatory signaling pathways.

Purpose: Modulate microglial activation through BTK pathway inhibition, reducing pro-inflammatory cytokine production

Drugs:

• Tolebrutinib (SAR442168): BTK inhibitor in late-stage clinical development

• Fenebrutinib (GDC-0853): Highly selective BTK inhibitor

Clinical Trials:

• Phase II/III trials for multiple sclerosis completed

• Phase II trials planned for Alzheimer’s disease

• Demonstrated reduced microglial activation in PET imaging studies

References: ^[5]^

PPAR-γ Agonists

Peroxisome Proliferator-Activated Receptor Gamma (PPAR-γ) is a nuclear receptor that regulates microglial inflammatory responses.

Purpose: Promote anti-inflammatory microglial phenotype and reduce neuroinflammation

Drugs:

• Pioglitazone: PPAR-γ agonist with demonstrated anti-inflammatory effects in preclinical models

• Diraglutide: GLP-1 receptor agonist with microglial modulatory effects

Clinical Status: Some evidence of reduced dementia risk in diabetic patients; clinical trials ongoing

Disease-Specific Applications

Alzheimer’s Disease

Microglia play a central role in Alzheimer’s disease pathophysiology:

• Amyloid Clearance: TREM2 variants affect the brain’s ability to clear amyloid plaques; microglial clustering around plaques is a hallmark finding

• Neuroinflammation: Chronic IL-1β and TNF-α release contributes to synaptic dysfunction and neuronal loss

• Tau Propagation: Microglia may facilitate spread of tau pathology through exosome release

• Therapeutic Target: CSF-1R inhibition reduces plaque-associated inflammation in mouse models

Parkinson’s Disease

Microglial activation in Parkinson’s disease contributes to dopaminergic neuron loss:

• Substantia Nigra Activation: Postmortem studies show extensive microglial activation in the substantia nigra of PD patients

• NLRP3 Involvement: Inflammasome activation contributes to dopaminergic neuron degeneration

• TREM2 Variants: Some TREM2 variants modify PD risk, suggesting microglial involvement

• Therapeutic Target: NLRP3 inhibitors may protect dopaminergic neurons

Amyotrophic Lateral Sclerosis (ALS)

Activated microglia drive motor neuron injury in ALS:

• Motor Cortex and Spinal Cord: Postmortem studies reveal extensive microglial activation in affected regions

• Pro-inflammatory Phenotype: Microglia adopt a predominantly pro-inflammatory (M1-like) phenotype

• CSF-1R Inhibition: Reduces microglial proliferation and slows disease progression in SOD1 mouse models

• Therapeutic Target: Combination approaches targeting multiple pathways in development

Multiple Sclerosis

While primarily an autoimmune demyelinating disease, microglial modulation is being explored:

• Tolebrutinib: Demonstrated efficacy in reducing disease activity in MS trials

• Microglial Phenotype: Understanding beneficial versus harmful microglial functions is critical

Biomarkers

Monitoring microglial activation is essential for clinical development:

Therapeutic Implications

Advantages:

• Targets upstream mechanisms of neuronal loss rather than downstream symptoms

• Potential for disease modification rather than merely symptomatic relief

• May work synergistically with anti-amyloid, anti-tau, or other targeted approaches

• Applicable across multiple neurodegenerative diseases with shared neuroinflammatory mechanisms

Challenges:

• Balancing beneficial versus harmful microglial functions is complex

• Microglia may have different roles at different disease stages

• Biomarker development needed to identify patients who will benefit

• Timing of intervention may be critical; late-stage intervention may be less effective

• CNS penetration of therapeutic agents remains a challenge

Future Directions:

• Combination therapies targeting multiple pathways

• Personalized approaches based on microglial genetics (e.g., TREM2 status)

• Disease-stage specific interventions

• Biomarker-guided patient selection

Research Directions

The field of microglial modulation is rapidly evolving:

• Microglial Phenotyping: Single-cell RNA sequencing is revealing heterogeneous microglial populations; understanding beneficial versus harmful phenotypes is key

• Targeted Delivery: Developing CNS-penetrant agents that selectively target microglia

• Combination Therapies: Rational combinations with anti-amyloid, anti-tau, or neuroprotective approaches

• Genetic Stratification: Patient selection based on microglial genetics (TREM2, PLCG2, CR1 variants)

• Imaging Biomarkers: TSPO PET imaging to visualize microglial activation in living patients

• Cell-Specific Targeting: Engineering therapeutics to selectively target disease-associated microglia

See Also

• Neuroinflammation Pathway

• TREM2 Targeting Therapies

• NLRP3 Inflammasome Inhibitors

• CSF-1R Inhibitors

• Alzheimer’s Disease

• Parkinson’s Disease

• ALS

• Microglia

External Links

• TREM2 Research Foundation

• Alzheimer’s Association: Microglia and Neuroinflammation

• PubMed: Microglia Neurodegeneration

• Allen Brain Atlas: Microglial Expression

Background

The study of microglia in neurodegeneration has evolved dramatically over the past two decades. Initially viewed primarily as destructive immune cells, our understanding has shifted to recognize the dual nature of microglia—both their potential for neuroprotection and their capacity to drive pathology.

Key historical developments include:

• 1990s: Recognition of microglia as the brain’s immune cells

• 2000s: Identification of TREM2 as risk gene for Alzheimer’s disease

• 2010s: Development of CSF-1R inhibitors for microglial depletion

• 2020s: Multiple clinical trials targeting TREM2, BTK, and NLRP3

This evolving understanding continues to shape therapeutic development and offers hope for disease-modifying treatments.